Literature DB >> 33656718

The Immune Response and Effectiveness of COVID-19 Therapies.

Fataneh Tavasolian1, Gholam Reza Hatam2, Sayed Hussain Mosawi3, Mahdiyar Iravani Saadi4, Elham Abdollahi5, Tannaz Jamialahmadi6,7,8, Thozhukat Sathyapalan9, Amirhossein Sahebkar10,11,12,13.   

Abstract

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly pathogenic with relatively high mortality and morbidity. In addition to pneumonia, acute respiratory distress syndrome, and microembolic disorder, a high proportion of patients with SARS-CoV-2 develop lymphopenia and cytokine storm disorder. This review explores the underlying mechanisms behind the pathogenesis of SARS-CoV-2, especially the immune mechanisms, which could be potentially used as therapeutic targets for the management of COVID-19.

Entities:  

Keywords:  COVID-19; Cytokine storm syndrome; Immune response; Lymphopenia

Year:  2021        PMID: 33656718     DOI: 10.1007/978-3-030-59261-5_10

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  8 in total

1.  Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).

Authors:  Bo Diao; Chenhui Wang; Yingjun Tan; Xiewan Chen; Ying Liu; Lifen Ning; Li Chen; Min Li; Yueping Liu; Gang Wang; Zilin Yuan; Zeqing Feng; Yi Zhang; Yuzhang Wu; Yongwen Chen
Journal:  Front Immunol       Date:  2020-05-01       Impact factor: 7.561

2.  Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2.

Authors:  Austin Nguyen; Julianne K David; Sean K Maden; Mary A Wood; Benjamin R Weeder; Abhinav Nellore; Reid F Thompson
Journal:  J Virol       Date:  2020-06-16       Impact factor: 5.103

Review 3.  Convalescent plasma in Covid-19: Possible mechanisms of action.

Authors:  Manuel Rojas; Yhojan Rodríguez; Diana M Monsalve; Yeny Acosta-Ampudia; Bernardo Camacho; Juan Esteban Gallo; Adriana Rojas-Villarraga; Carolina Ramírez-Santana; Juan C Díaz-Coronado; Rubén Manrique; Ruben D Mantilla; Yehuda Shoenfeld; Juan-Manuel Anaya
Journal:  Autoimmun Rev       Date:  2020-05-05       Impact factor: 9.754

Review 4.  The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease.

Authors:  Dennis McGonagle; Kassem Sharif; Anthony O'Regan; Charlie Bridgewood
Journal:  Autoimmun Rev       Date:  2020-04-03       Impact factor: 9.754

Review 5.  Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Authors:  Bingwen Liu; Min Li; Zhiguang Zhou; Xuan Guan; Yufei Xiang
Journal:  J Autoimmun       Date:  2020-04-10       Impact factor: 7.094

6.  Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.

Authors:  Yehuda Shoenfeld
Journal:  Autoimmun Rev       Date:  2020-04-05       Impact factor: 9.754

7.  Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?

Authors:  Andrew I Ritchie; Aran Singanayagam
Journal:  Lancet       Date:  2020-03-24       Impact factor: 79.321

8.  Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.

Authors:  Chi Zhang; Zhao Wu; Jia-Wen Li; Hong Zhao; Gui-Qiang Wang
Journal:  Int J Antimicrob Agents       Date:  2020-03-29       Impact factor: 5.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.